Dupilumab (Regeneron/Sanofi) is an injectable monoclonal antibody directed against the interleukin (IL)-4 receptor alpha subunit, which blocks signaling from both IL-4 and IL-13. Dupilumab is in Phase III development for both asthma and atopic dermatitis.
While dupilumab (Regeneron/Sanofi) has demonstrated positive efficacy in its Phase IIb study and acts via a novel mechanism of action, inhibiting signaling of interleukin (IL)-4 and IL-13, there are limited data currently available and the drug’s potential in asthma is not yet clear. Furthermore, dupilumab’s development for asthma lags behind several other biologics, with its pivotal Phase III Liberty Asthma Quest study initiated in April 2015. With limited data currently available, Datamonitor Healthcare does not provide a forecast for dupilumab in asthma at this time.
LIST OF FIGURES
6 Figure 1: Dupilumab for asthma – SWOT analysis
7 Figure 2: Datamonitor Healthcare’s drug assessment summary of dupilumab in asthma
8 Figure 3: Datamonitor Healthcare’s drug assessment summary of dupilumab in asthma
15 Figure 4: Dupilumab for atopic dermatitis – SWOT analysis
16 Figure 5: Datamonitor Healthcare’s drug assessment summary of dupilumab in atopic
16 Figure 6: Datamonitor Healthcare’s drug assessment summary of dupilumab in atopic
LIST OF TABLES
4 Table 1: Dupilumab drug profile
5 Table 2: Dupilumab Phase III trials in asthma
10 Table 3: Dupilumab drug profile
13 Table 4: Dupilumab Phase III trials in atopic dermatitis
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.